Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03414658 · ClinicalTrials.gov registry record · Phase 2
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by Adrienne G. Waks.
- Active
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 17
- Study locations
NCT03414658: Active Phase 2 study of Breast Cancer, sponsored by Adrienne G. Waks.
NCT03414658 is a Phase 2 study of Breast Cancer that is active but no longer recruiting, run by Adrienne G. Waks. The registered enrollment target is 100 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 17 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03414658, a Phase 2 study of Breast Cancer, is active but no longer recruiting, sponsored by Adrienne G. Waks.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 17
- Study locations
Study Summary
This research study is studying a combination of drugs as a possible treatment for breast cancer. The drugs involved in this study are: * Group A: Trastuzumab (Herceptin) + Vinorelbine (Navelbine) * Group B: Trastuzumab + Vinorelbine + Avelumab * Group C: Trastuzumab + Vinorelbine + Avelumab + Utomilumab (PF-05082566)
Primary Outcome
Progression Free Survival is defined from the time from randomization to the first occurrence of disease progression as determined by the investigator using RECIST 1.1 or death from any cause, whichever occurs first.
Conditions Studied
Interventions
- DRUG Trastuzumab
- DRUG Avelumab
- DRUG Vinorelbine
- DRUG Utomilumab
Study Locations (17)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
New York
- Memorial Sloan-Kettering Cancer Center - New York
- Montefiore Medical Center - The Bronx
North Carolina
- University of Carolina at Chapel Hill - Chapel Hill
- Duke University Medical Center - Durham
Texas
- Baylor College of Medicine - Houston
- MD Anderson Cancer Center - Houston
Alabama
- University of Alabama at Birmingham - Birmingham
California
- University of California San Francisco - San Francisco
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Illinois
- University of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-06-21 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 2 |
What the registry record for NCT03414658 still lists
NCT03414658 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Trastuzumab is the first listed.
NCT03414658 lists 17 locations in 13 states (Massachusetts, New York, North Carolina).
Frequently Asked Questions
What is clinical trial NCT03414658 about?
NCT03414658 is a clinical study titled "The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer". This research study is studying a combination of drugs as a possible treatment for breast cancer. The drugs involved in this study are: * Group A: Trastuzumab (Herceptin) + Vinorelbine (Navelbine) * Group B: Trastuzumab + Vinorelbine + Avelumab * Group C: Trastuzumab + Vinorelbine + Avelumab + Uto...
What is the current status of trial NCT03414658?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2018-06-21. Estimated completion is 2026-05-31.
What conditions does trial NCT03414658 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT03414658?
The interventions under investigation include: Trastuzumab (DRUG), Avelumab (DRUG), Vinorelbine (DRUG), Utomilumab (DRUG).
Who is sponsoring clinical trial NCT03414658?
This trial is sponsored by Adrienne G. Waks, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03414658 being conducted?
This trial has 17 study locations across Alabama, California, District of Columbia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03414658's enrollment target sits among peer trials
100 565th of 1224 higher than 630 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI